BRPI0810140A2 - Composição de microempresa biodegradável adequada para a liberação controlada de um peptídeo de controle de glicose e formulação da mesma - Google Patents

Composição de microempresa biodegradável adequada para a liberação controlada de um peptídeo de controle de glicose e formulação da mesma

Info

Publication number
BRPI0810140A2
BRPI0810140A2 BRPI0810140-0A2A BRPI0810140A BRPI0810140A2 BR PI0810140 A2 BRPI0810140 A2 BR PI0810140A2 BR PI0810140 A BRPI0810140 A BR PI0810140A BR PI0810140 A2 BRPI0810140 A2 BR PI0810140A2
Authority
BR
Brazil
Prior art keywords
formulation
same
controlled release
composition suitable
control peptide
Prior art date
Application number
BRPI0810140-0A2A
Other languages
English (en)
Inventor
Hyun Hee Kwak
Ghun Ii Lee
Yong Man Park
Hi Chang Yang
Tae Hyoung Kim
Sung Hee Lee
Soo Hyung Kang
Moohi Yoo
Mi Kyung Son
Yoon Ji Kim
Byong Moon Kim
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of BRPI0810140A2 publication Critical patent/BRPI0810140A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0810140-0A2A 2007-04-19 2008-04-18 Composição de microempresa biodegradável adequada para a liberação controlada de um peptídeo de controle de glicose e formulação da mesma BRPI0810140A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070038467 2007-04-19
PCT/KR2008/002216 WO2008130158A1 (en) 2007-04-19 2008-04-18 A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof

Publications (1)

Publication Number Publication Date
BRPI0810140A2 true BRPI0810140A2 (pt) 2014-10-29

Family

ID=39875642

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810140-0A2A BRPI0810140A2 (pt) 2007-04-19 2008-04-18 Composição de microempresa biodegradável adequada para a liberação controlada de um peptídeo de controle de glicose e formulação da mesma

Country Status (14)

Country Link
US (1) US8282990B2 (pt)
EP (1) EP2139458A4 (pt)
JP (1) JP5302952B2 (pt)
KR (2) KR101034888B1 (pt)
CN (1) CN101657190B (pt)
AU (1) AU2008241699B2 (pt)
BR (1) BRPI0810140A2 (pt)
CA (1) CA2683698C (pt)
CO (1) CO6241098A2 (pt)
IL (1) IL201523A0 (pt)
MX (1) MX2009011275A (pt)
NZ (1) NZ580700A (pt)
RU (1) RU2422134C1 (pt)
WO (1) WO2008130158A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448482A (zh) 2009-03-27 2012-05-09 范安德尔研究所 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
CN102370624A (zh) * 2010-08-17 2012-03-14 东莞太力生物工程有限公司 Exendin-4缓释微球及其注射剂和该缓释微球的制备方法
JP5886749B2 (ja) * 2010-09-02 2016-03-16 日本化薬株式会社 薬物−ブロックコポリマー複合体とそれを含有する医薬の製造方法
KR101785515B1 (ko) * 2010-11-08 2017-10-16 에스케이케미칼주식회사 올란자핀 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물
KR20120048811A (ko) * 2010-11-08 2012-05-16 에스케이케미칼주식회사 아나스트로졸 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
US9415123B2 (en) 2011-10-10 2016-08-16 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
JP6392123B2 (ja) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 糖尿病治療のためのｃｔｐ系インスリンアナローグ
KR20150023729A (ko) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체
BR112014031671A2 (pt) 2012-06-21 2018-08-07 Hoffmann La Roche análogos de glucagon exibindo atividade de receptor gip
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリンアナローグダイマー
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
KR101486132B1 (ko) * 2013-03-20 2015-01-23 씨제이헬스케어 주식회사 졸-겔 변환 특성을 갖는 고분자를 이용한 미립구의 제조방법 및 이로부터 제조된 미립구
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
EP3250611B1 (en) 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
US20180201937A1 (en) 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
ES2960753T3 (es) 2015-09-21 2024-03-06 Teva Pharmaceuticals Int Gmbh Formulaciones de olanzapina de liberación sostenida
KR101706254B1 (ko) * 2015-11-17 2017-02-13 주식회사 동일팜텍 생체조직 수복 또는 재생용 고분자 미세입자의 제조방법
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
CN110996953A (zh) 2017-06-30 2020-04-10 安进公司 用心脏肌小节激活剂治疗心力衰竭的方法
BR122021015266B1 (pt) 2017-08-03 2023-01-24 Amgen Inc. Conjugado compreendendo muteína de il-21 e anticorpo anti-pd, kit e composição farmacêutica
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
SG11202002114RA (en) 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
JP7054954B2 (ja) * 2018-01-10 2022-04-15 ジー２ジーバイオ インコーポレイテッド コラーゲンペプチドを含有したポリカプロラクトン微粒球フィラーおよびその製造方法
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
KR102137786B1 (ko) * 2018-07-19 2020-07-24 주식회사 아울바이오 주사제용 미립구의 제조방법
RU2696773C1 (ru) * 2018-08-13 2019-08-06 Алексей Николаевич Осинцев Способ получения лекарственного препарата пептидной природы с контролируемым и последовательным высвобождением
WO2020055913A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of reducing- c-reactive protein and/or treating cardiovascular disease
KR20210154158A (ko) 2019-03-20 2021-12-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 클라우딘-6 항체 및 약물 컨쥬게이트
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
WO2020210376A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
WO2020222668A1 (en) 2019-04-30 2020-11-05 Instituto de Medicina Molecular João Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
WO2020263793A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
US20220280561A1 (en) 2019-08-30 2022-09-08 Research Institute At Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associted with mitochondrial dysfunction
KR102583029B1 (ko) * 2020-05-28 2023-09-26 주식회사 아울바이오 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
KR102469409B1 (ko) * 2020-08-24 2022-11-23 주식회사 메피온 색전물질 제조 방법
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
CA3208974A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
CN114588115B (zh) * 2022-04-20 2023-01-13 上海瑞凝生物科技有限公司 一种plga药物缓释微球的制备方法
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
SE512663C2 (sv) * 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
DE69923795T2 (de) * 1998-12-15 2006-03-16 Takeda Pharmaceutical Co. Ltd. Verfahren zur Herstellung biologisch-abbaubarer Polyester
US6689747B2 (en) * 2000-03-24 2004-02-10 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
AU2001266392A1 (en) * 2000-06-27 2002-01-08 Mi Tech Company Limited The controlled release preparation of insulin and its method
CA2432900C (en) * 2000-12-21 2007-09-11 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophilic active agents
WO2002074340A1 (fr) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
JP2003212758A (ja) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd 徐放性製剤の製造法
KR100566573B1 (ko) * 2002-04-13 2006-03-31 주식회사 펩트론 Ｌｈｒｈ 동족체를 함유하는 서방성 미립구의 제조방법
JP5165239B2 (ja) * 2003-07-15 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 制御放出処方物の調製のための方法
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
ES2536235T3 (es) 2004-04-15 2015-05-21 Alkermes Pharma Ireland Limited Dispositivo polimérico de liberación prolongada
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법

Also Published As

Publication number Publication date
JP2010524924A (ja) 2010-07-22
CN101657190A (zh) 2010-02-24
US8282990B2 (en) 2012-10-09
IL201523A0 (en) 2010-05-31
RU2009142608A (ru) 2011-05-27
AU2008241699A1 (en) 2008-10-30
US20100129459A1 (en) 2010-05-27
CA2683698A1 (en) 2008-10-30
JP5302952B2 (ja) 2013-10-02
WO2008130158A1 (en) 2008-10-30
AU2008241699B2 (en) 2011-02-03
CO6241098A2 (es) 2011-01-20
NZ580700A (en) 2012-01-12
KR101034888B1 (ko) 2011-05-17
EP2139458A1 (en) 2010-01-06
CN101657190B (zh) 2013-09-11
EP2139458A4 (en) 2013-01-23
KR20080094616A (ko) 2008-10-23
CA2683698C (en) 2013-09-10
RU2422134C1 (ru) 2011-06-27
KR20110044192A (ko) 2011-04-28
MX2009011275A (es) 2009-11-02

Similar Documents

Publication Publication Date Title
BRPI0810140A2 (pt) Composição de microempresa biodegradável adequada para a liberação controlada de um peptídeo de controle de glicose e formulação da mesma
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
BRPI0911504A2 (pt) composição polimérica e uso da mesma, artigo com superfície granulada e uso de uma composição polimérica para a produção de um artigo
BRPI0809125A2 (pt) composições sinergísticas para controle de pragas
BRPI0910335A2 (pt) composição herbicida, uso da mesma, método para controlar vegetação indesejável, e, formulação herbicida
BRPI0816991A2 (pt) Formulação, processo para preparar a mesma, e, usos de uma composição antimicrobiana e de uma formulação
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
BRPI0817423A2 (pt) Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
BRPI0910337A2 (pt) composição herbicida, uso da mesma, método para controlar vegetação indesejável e, formulação herbicida
BRPI0914926A2 (pt) uso de benzotropolona e derivados da mesma, composição cosmética, compostos, e, método para sintetizar um derivado de benzotropolona
BRPI0907914A2 (pt) Tiras de filme comestível com ingrediente ativo com liberação modificada
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0811996A2 (pt) Composição amaciante para tecido, e, método para amaciar um tecido
BRPI0806993A2 (pt) Estruturas de salto para sinais piloto de banda larga
BRPI0818906A2 (pt) Formulação sólida de liberação rápida, preparação e uso da mesma
BRPI0819786A2 (pt) Forma crsitalina, processos para a preparação da forma cristalina e para estabilizar um material orgânico contra degradação induzida pela luz, mistura estabilizadora, composição, e, artigo feito de uma composição
BRPI0908162A2 (pt) Composição herbicida, uso de uma composição, método para controlar vegetação indesejavel, e, formulação herbicida
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI0910059A2 (pt) Composição sólida para controle de praga
HK1198743A1 (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
BRPI1011412A2 (pt) composição para liberação sustentada de droga compreendendo alutinante geopolimérico
BRPI0821327A2 (pt) Derivado de catecol, composição farmacêutica contendo o mesmo, uso do derivado de catecol, e uso da composição farmacêutica
BRPI0922670A2 (pt) material de revestimento para uma formulação sólida, e, formulação sólida
BR112012024638A2 (pt) uso de um copolímero de enxerto, composição, método para preparação da composição e método para controle

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]